Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

Phase 1  | ENROLLING

NCT04148937

Advanced Solid Tumors

CD73 Inhibitor


A Phase 1 Multicenter Global First-in-Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies*

NCT04148937
Key Inclusion Criteria
  • Certain types of cancer such as breast, pancreatic, lung, kidney, skin (melanoma), prostate, or ovarian
  • Stopped other forms of treatment for the cancer
  • Able and willing to provide a sample of the tumor before beginning treatment and a sample during the treatment
  • Not pregnant and agrees to use birth control
  • Progressed through or intolerant to therapies with known clinical benefit
Key Exclusion Criteria
  • Current untreated tuberculosis, lung disease, heart disease, uncontrolled HIV, autoimmune disease, active hepatitis B or C virus infection, or using corticosteroids
  • Cancer that has spread to the brain
  • Received a vaccine within the last 30 days
  • Bowel obstruction within the last 6 months, or intestinal surgery
  • An infection that is currently being treated
*
This clinical trial is being conducted globally.
LY3475070 is administered PO.
Pembrolizumab is administered intravenously.
Contact the Loxo Oncology at Lilly Clinical Trial Team

Visit www.clinicaltrials.gov for more information on this trial.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.